home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0275.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
2KB
|
36 lines
Document 0275
DOCN M94A0275
TI Treatment of oropharyngeal candidiasis in HIV-positive patients.
DT 9412
AU Greenspan D; Department of Stomatology, University of California San
Francisco; 94143-0422.
SO J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S51-5. Unique Identifier :
AIDSLINE MED/94358249
AB Most HIV-positive patients develop some form of oral candidiasis, most
commonly pseudomembranous candidiasis, erythematous candidiasis, or
angular cheilitis, at some point in their disease. All these
manifestations are important risk markers for disease progression. Oral
candidiasis is generally caused by Candida albicans. Although oral
candidiasis can occur at any stage of HIV infection, it is most common
in patients with low CD4 counts. Numerous oral and systemic therapies
are used to treat oral candidiasis, the most popular of which are
nystatin (topical), clotrimazole (topical), ketoconazole (systemic),
fluconazole (systemic), and itraconazole (systemic). The topical agents
are available in assorted dosage forms with varying degrees of efficacy
and patient acceptability. The limited data currently available suggest
an advantage for the systemic agents, although problems with resistance
may limit the usefulness of fluconazole. The efficacy, safety, and cost
effectiveness of a given agent must be considered when prescribing a
specific agent for the treatment of oral candidiasis.
DE Administration, Oral Administration, Topical Antifungal
Agents/*THERAPEUTIC USE Candidiasis,
Oral/*COMPLICATIONS/DIAGNOSIS/*DRUG THERAPY/ IMMUNOLOGY
Clotrimazole/THERAPEUTIC USE Fluconazole/THERAPEUTIC USE Human HIV
Infections/*COMPLICATIONS Ketoconazole/THERAPEUTIC USE Leukocyte Count
Nystatin/THERAPEUTIC USE Risk Factors T4 Lymphocytes/IMMUNOLOGY
JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).